ANN ARBOR (WWJ) – Ann Arbor-based Molecular Imaging Inc. said Thursday it had a collaboration and co-promotion agreement with Freiburg, Germany-based Oncotest GmbH.
Under the agreement, both companies will promote the ability to perform Oncotest’s patient-derived xenograft pharmacology studies with the imaging capabilities of Molecular Imaging Inc.
Xenografts are grafts of tissues from one species to another — in this case, using human cancer tissue in laboratory animals for the purposes of selecting and developing new cancer drugs.
Molecular Imaging is a specialty contract research organization providing in vivo preclinical imaging services. The company’s pharmaco-imaging platform includes MRI, PET, bioluminescence, fluorescence, and micro-CT. The company has performed more than 2,000 cell line based traditional oncology studies and more than 500 imaging enhanced studies since its founding in 2003.
Oncotest was founded in 1993 by Heinz-Herbert Fiebig, M.D., from his pioneering work in predicting the response of a patient towards cancer drugs by using patient tumor material. Oncotest has established and comprehensively molecularly and pharmacologically profiled more than 350 PDX models covering a wide variety of tumor types that offer direct connection to the clinic.
More at http://www.molecularimaging.com .